Related Experiment Video
Updated: Jun 16, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement
Cristian P Ilie1, Michael B Chancellor, Yao-Chi Chuang
1Urology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. dr.cristianilie@gmail.com
Journal of Medicine and Life
|January 30, 2010
Summary
Botulinum toxin (BTX-A) shows promise for treating benign prostatic hyperplasia (BPH) by safely and effectively alleviating symptoms. Further research is needed to confirm its mechanisms, optimal dosage, and duration of effect for BPH management.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is highly prevalent in aging men, affecting over 50% of those over 50.
- Current BPH treatments include watchful waiting, medical therapy, and surgery, each with varying efficacy and risks.
Purpose of the Study:
- To evaluate the safety and efficacy of Botulinum toxin type A (BTX-A) as a novel therapeutic option for BPH.
- To explore the potential mechanisms of BTX-A in treating BPH symptoms.
Main Methods:
- BTX-A's mechanism involves inhibiting acetylcholine release, causing muscle fiber atrophy.
- It also affects the autonomic nervous system, potentially inducing prostate gland atrophy and apoptosis.
Main Results:
- Clinical studies indicate that BTX-A is effective in relieving BPH-induced symptoms.
- Prostate injections of BTX-A appear to be safe in clinical practice.
Conclusions:
- BTX-A demonstrates potential as a safe and effective treatment for alleviating BPH symptoms.
- Larger randomized clinical trials are required to elucidate BTX-A's precise mechanisms, optimal dosing, and duration of therapeutic effect in BPH.
